{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:17:14Z","timestamp":1783826234732,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The progressive patterns of neurological disability in multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) and the significance of clinical relapses to the progressions of neurological disability in these diseases have not been fully elucidated. In this study, to elucidate the impact of relapses to the progression of accumulated neurological disability and to identify the factors to affect the progression of neurological disability in MS and NMOSD, we followed 62 consecutive MS patients and 33 consecutive NMOSD patients for more than 5\u00a0years with the clinical symptoms, relapse occurrence, and Expanded Disability Status Scale (EDSS) in the chronic phase. All enrolled MS patients were confirmed to be negative for serum anti-myelin oligodendrocyte glycoprotein antibody. As a result, patients with NMOSD showed significantly severer neurological disability at 5\u00a0years from onset than MS patients. Progression in EDSS score was almost exclusively seen after clinical attacks in NMOSD, whereas progression could be observed apart from relapses in MS. Neurological disability did not change without attacks in NMOSD, whereas it sometimes spontaneously improved or deteriorated apart from relapses in MS (p\u2009&lt;\u20090.001). In patients with MS, those with responsible lesions primarily in spinal cord were more likely to show such spontaneous improvement. In conclusion, clinical deterioration in NMOSD patients is irreversible and almost exclusively takes place at the timing of clinical attacks with stepwise accumulation of neurological disability. Meanwhile, changes in EDSS score can be seen apart from relapses in MS patients. Neurological disability in MS patients is partly reversible, and the patients with disease modifying drugs sometimes present spontaneous improvement of the neurological disability.<\/jats:p>","DOI":"10.1038\/s41598-020-70919-w","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T10:02:45Z","timestamp":1597658565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders"],"prefix":"10.1038","volume":"10","author":[{"given":"Tetsuya","family":"Akaishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juichi","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"70919_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85, 177\u2013189. https:\/\/doi.org\/10.1212\/wnl.0000000000001729 (2015).","journal-title":"Neurology"},{"key":"70919_CR2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","volume":"9","author":"N Borisow","year":"2018","unstructured":"Borisow, N., Mori, M., Kuwabara, S., Scheel, M. & Paul, F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front. Neurol. 9, 888. https:\/\/doi.org\/10.3389\/fneur.2018.00888 (2018).","journal-title":"Front. Neurol."},{"key":"70919_CR3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1212\/wnl.0000000000001367","volume":"84","author":"HJ Kim","year":"2015","unstructured":"Kim, H. J. et al. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology 84, 1165\u20131173. https:\/\/doi.org\/10.1212\/wnl.0000000000001367 (2015).","journal-title":"Neurology"},{"key":"70919_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann. Neurol. 69, 292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366 (2011).","journal-title":"Ann. Neurol."},{"key":"70919_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3988\/jcn.2018.14.3.387","volume":"14","author":"V Mantero","year":"2018","unstructured":"Mantero, V., Abate, L., Balgera, R., La Mantia, L. & Salmaggi, A. Clinical application of 2017 McDonald diagnostic criteria for multiple sclerosis. J. Clin. Neurol. 14, 387\u2013392. https:\/\/doi.org\/10.3988\/jcn.2018.14.3.387 (2018).","journal-title":"J. Clin. Neurol."},{"key":"70919_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 Revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173. https:\/\/doi.org\/10.1016\/s1474-4422(17)30470-2 (2018).","journal-title":"Lancet Neurol."},{"key":"70919_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/wco.0000000000000694","volume":"32","author":"K Fujihara","year":"2019","unstructured":"Fujihara, K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr. Opin. Neurol. 32, 385\u2013394. https:\/\/doi.org\/10.1097\/wco.0000000000000694 (2019).","journal-title":"Curr. Opin. Neurol."},{"key":"70919_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/wco.0000000000000195","volume":"28","author":"D Ontaneda","year":"2015","unstructured":"Ontaneda, D. & Fox, R. J. Progressive multiple sclerosis. Curr. Opin. Neurol. 28, 237\u2013243. https:\/\/doi.org\/10.1097\/wco.0000000000000195 (2015).","journal-title":"Curr. Opin. Neurol."},{"key":"70919_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/wnl.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83, 278\u2013286. https:\/\/doi.org\/10.1212\/wnl.0000000000000560 (2014).","journal-title":"Neurology"},{"key":"70919_CR10","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann, H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front. Immunol. 9, 3116. https:\/\/doi.org\/10.3389\/fimmu.2018.03116 (2018).","journal-title":"Front. Immunol."},{"key":"70919_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/nyas.12794","volume":"1366","author":"SJ Pittock","year":"2016","unstructured":"Pittock, S. J. & Lucchinetti, C. F. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: A decade later. Ann. N. Y. Acad. Sci. 1366, 20\u201339. https:\/\/doi.org\/10.1111\/nyas.12794 (2016).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"70919_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jamaneurol.2013.5055","volume":"71","author":"Y Jiao","year":"2014","unstructured":"Jiao, Y. et al. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol. 71, 48\u201354. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5055 (2014).","journal-title":"JAMA Neurol."},{"key":"70919_CR13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","volume":"81","author":"Y Jiao","year":"2013","unstructured":"Jiao, Y. et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 81, 1197\u20131204. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a6cb5c (2013).","journal-title":"Neurology"},{"key":"70919_CR14","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/wnl.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk, D. M., Hogancamp, W. F., O\u2019Brien, P. C. & Weinshenker, B. G. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53, 1107\u20131114. https:\/\/doi.org\/10.1212\/wnl.53.5.1107 (1999).","journal-title":"Neurology"},{"key":"70919_CR15","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/nxi.0000000000000089","volume":"2","author":"P Waters","year":"2015","unstructured":"Waters, P. et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol. Neuroimmunol. Neuroinflamm. 2, e89. https:\/\/doi.org\/10.1212\/nxi.0000000000000089 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"70919_CR16","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi, T. et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 130, 1235\u20131243. https:\/\/doi.org\/10.1093\/brain\/awm062 (2007).","journal-title":"Brain"},{"key":"70919_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1620\/tjem.210.307","volume":"210","author":"T Takahashi","year":"2006","unstructured":"Takahashi, T. et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J. Exp. Med. 210, 307\u2013313. https:\/\/doi.org\/10.1620\/tjem.210.307 (2006).","journal-title":"Tohoku J. Exp. Med."},{"key":"70919_CR18","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33, 1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444 (1983).","journal-title":"Neurology"},{"key":"70919_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jneuroim.2017.03.009","volume":"306","author":"T Akaishi","year":"2017","unstructured":"Akaishi, T., Nakashima, I., Mugikura, S., Aoki, M. & Fujihara, K. Whole brain and grey matter volume of Japanese patients with multiple sclerosis. J. Neuroimmunol. 306, 68\u201375. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.03.009 (2017).","journal-title":"J. Neuroimmunol."},{"key":"70919_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/jnnp.2006.105759","volume":"78","author":"L Costelloe","year":"2007","unstructured":"Costelloe, L. et al. The patient knows best: Significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J. Neurol. Neurosurg. Psychiatry 78, 841\u2013844. https:\/\/doi.org\/10.1136\/jnnp.2006.105759 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"70919_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2017.10.001","volume":"313","author":"T Akaishi","year":"2017","unstructured":"Akaishi, T. et al. Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica. J. Neuroimmunol. 313, 10\u201315. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.10.001 (2017).","journal-title":"J. Neuroimmunol."},{"key":"70919_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree, B. A. C. et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann. Neurol. 85, 653\u2013666. https:\/\/doi.org\/10.1002\/ana.25463 (2019).","journal-title":"Ann. Neurol."},{"key":"70919_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1212\/01.wnl.0000316799.86917.37","volume":"71","author":"LC Silbert","year":"2008","unstructured":"Silbert, L. C., Nelson, C., Howieson, D. B., Moore, M. M. & Kaye, J. A. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 71, 108\u2013113. https:\/\/doi.org\/10.1212\/01.wnl.0000316799.86917.37 (2008).","journal-title":"Neurology"},{"key":"70919_CR24","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/brain\/aww009","volume":"139","author":"C Lambert","year":"2016","unstructured":"Lambert, C. et al. Longitudinal patterns of leukoaraiosis and brain atrophy in symptomatic small vessel disease. Brain 139, 1136\u20131151. https:\/\/doi.org\/10.1093\/brain\/aww009 (2016).","journal-title":"Brain"},{"key":"70919_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/wnl.0000000000003542","volume":"88","author":"MA Rocca","year":"2017","unstructured":"Rocca, M. A. et al. Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology 88, 403\u2013413. https:\/\/doi.org\/10.1212\/wnl.0000000000003542 (2017).","journal-title":"Neurology"},{"key":"70919_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000640","author":"T Akaishi","year":"2020","unstructured":"Akaishi, T. et al. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol. Neuroimmunol. Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000000640 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"70919_CR27","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1212\/wnl.0000000000001520","volume":"84","author":"BG Weinshenker","year":"2015","unstructured":"Weinshenker, B. G. et al. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology 84, 1805\u20131815. https:\/\/doi.org\/10.1212\/wnl.0000000000001520 (2015).","journal-title":"Neurology"},{"key":"70919_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402\u2013415. https:\/\/doi.org\/10.1056\/NEJMoa0907839 (2010).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70919-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70919-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70919-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:49:48Z","timestamp":1670348988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70919-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70919"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70919-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13890"}}